Agile Therapeutics Inc AGRX
We take great care to ensure that the data presented and summarized in this overview for AGILE THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AGRX
Top Purchases
Top Sells
About AGRX
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Insider Transactions at AGRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 26
2024
|
Geoffrey Gilmore Chief Administrative Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,256
-74.99%
|
$20,256
$1.52 P/Share
|
|
Aug 26
2024
|
Amy Welsh Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,500
-87.5%
|
$13,500
$1.52 P/Share
|
|
Aug 26
2024
|
Paul Korner Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,500
-87.5%
|
$13,500
$1.52 P/Share
|
|
Aug 26
2024
|
Robert G Conway Chief Supply Chain Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,529
-87.42%
|
$13,529
$1.52 P/Share
|
|
Aug 26
2024
|
Scott M Coiante Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,080
-87.35%
|
$20,080
$1.52 P/Share
|
|
Aug 26
2024
|
Sharon Barbari Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
973
-100.0%
|
$973
$1.52 P/Share
|
|
Aug 26
2024
|
Josephine Torrente Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
987
-50.66%
|
$987
$1.52 P/Share
|
|
Aug 26
2024
|
John W Hubbard Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
976
-100.0%
|
$976
$1.52 P/Share
|
|
Aug 26
2024
|
Seth H. Z. Fischer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
976
-100.0%
|
$976
$1.52 P/Share
|
|
Aug 26
2024
|
Alfred Altomari Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
47,749
-79.45%
|
$47,749
$1.52 P/Share
|
|
Aug 26
2024
|
Sandra Carson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
973
-100.0%
|
$973
$1.52 P/Share
|
|
Oct 03
2023
|
Scott M Coiante Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+49.9%
|
-
|
|
Jun 28
2023
|
Geoffrey Gilmore Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,216
+37.41%
|
-
|
|
Jun 28
2023
|
Robert G Conway Chief Supply Chain Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+49.95%
|
-
|
|
Jun 28
2023
|
Alfred Altomari Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,463
+32.48%
|
-
|
|
Jun 28
2023
|
Paul Korner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+50.0%
|
-
|
|
Jun 28
2023
|
Amy Welsh Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+50.0%
|
-
|
|
Jun 08
2023
|
John W Hubbard Director |
BUY
Grant, award, or other acquisition
|
Direct |
935
+48.93%
|
-
|
|
Jun 08
2023
|
Seth H. Z. Fischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
935
+48.93%
|
-
|
|
Jun 08
2023
|
Josephine Torrente Director |
BUY
Grant, award, or other acquisition
|
Direct |
935
+48.62%
|
-
|
Last 12 Months Summary
| Sale (or disposition) back to the issuer | 133K shares |
|---|